|
Variables
|
Total (n = 701)
|
150 mg and 110 mg twice daily (n = 675)
|
75 mg twice daily (n = 26)
|
P-value
|
|---|
|
Age, years
|
71.1 ± 10.9
|
70.8 ± 10.8
|
78.6 ± 10.0
|
0.004**
|
|
Gender, female (%)
|
244 (34.8%)
|
231 (34.2%)
|
13 (50.0%)
|
0.098*
|
|
Creatinine clearance: Ccr (mL/min)
|
68.7 ± 25.3
|
69.4 ± 25.3
|
53.5 ± 20.9
|
0.003*
|
|
History of bleeding
|
79 (11.3%)
|
74 (11.0%)
|
5 (19.2%)
|
0.191***
|
|
New users
|
354 (50.5%)
|
348 (51.6%)
|
6 (23.1%)
|
0.004***
|
|
Change from warfarin
|
232 (33.1%)
|
222 (32.9%)
|
10 (38.5%)
|
0.532***
|
|
C: Congestive heart failure
|
138 (19.7%)
|
128 (19.0%)
|
10 (38.5%)
|
0.002***
|
|
H: Hypertension
|
426 (60.8%)
|
406 (60.1%)
|
20 (76.9%)
|
0.041**
|
|
A: Aged 75 or older
|
294 (41.9%)
|
278 (41.2%)
|
16 (61.5%)
|
0.021**
|
|
D: Diabetes Mellitus
|
140 (20.0%)
|
133 (19.7%)
|
7 (26.9%)
|
0.117***
|
|
S: Stroke/TIA (2 points)
|
185 (26.4%)
|
177 (26.2%)
|
8 (30.8%)
|
0.327***
|
|
CHADS2 score
|
1.95 ± 1.35
|
1.92 ± 1.33
|
2.54 ± 1.77
|
0.011*
|
|
With antiplatelet agents
|
129 (18.4%)
|
125 (18.5%)
|
4 (15.4%)
|
0.686***
|
- Mean ± S.D., * t-test, ** Chi-square test, *** Fisher’s exact test
